ISSN (print) 1997-6933     ISSN (online) 2500-2139
Vol. 18 No. 2 (2025), LYMPHOID TUMORS
Vol. 18 No. 2 (2025)
LYMPHOID TUMORS

Current Strategy and Principles of Multiple Myeloma Treatment: A Literature Review

Published 01.04.2025
Aleksander Sergeevich Luchinin
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0009-0006-0020-3168
A.A. Semenova
NN Blokhin National Medical Cancer Research Center, 23 Kashirskoye sh., Moscow, Russian Federation, 115522
https://orcid.org/0000-0003-4951-3053
S.V. Semochkin
NI Pirogov Russian National Research Medical University, 1 Ostrovityanova ul., Moscow, Russian Federation, 117997; PA Gertsen Moscow Oncology Research Institute, branch of the NMRC of Radiology, 3 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284
https://orcid.org/0000-0002-8129-8114
2025-2
PDF_2025-18-2-153-162 (Russian)

Keywords

multiple myeloma
treatment strategy

How to Cite

Luchinin A.S., Semenova A.A., Semochkin S.V. Current Strategy and Principles of Multiple Myeloma Treatment: A Literature Review. Clinical Oncohematology. 2025;(2):153–162. doi:10.21320/2500-2139-2025-18-2-153-162.
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA ГОСТ

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Statistics

Annotation views: 7
PDF_2025-18-2-153-162 (Russian) downloads: 11

Keywords

Abstract

In recent decades, multiple myeloma (ММ) has no longer been regarded as an incurable orphan malignancy, but has been rather considered to be a chronic disease with substantially improving options of treatment based on the new classes of chemotherapy drugs. Insight into biology of MM as well as the development and introduction of new drugs into clinical practice considerably improved survival rates. Risk stratification of MM patients on the basis of cytogenetic and molecular genetic analyses is now regarded as a key approach to the optimal treatment decision making. High-risk and aggressive MM patients are predominantly treated with combined chemotherapy protocols with 3–5 drugs including new effective agents of different classes (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, etc.). Apart from the risk assessment, an important tool for clinical decision making is minimal residual disease (MRD) monitoring. Achieving MRD-negativity is associated with better survival rates which allow further development of response-adapted treatment strategies. Perspectives for the precision (personalized) MM treatment are still limited due to the extreme heterogeneity of molecular genetic landscape of the tumor. Further studies are necessary to prove the efficacy of this approach. Thus, the current MM therapy is based on the assessment of risk parameters using the results of standard cytogenetic and molecular genetic analyses, MRD monitoring, and personalized approach, all of which provide a considerable improvement of both immediate and long-term outcomes of MM treatment.

PDF_2025-18-2-153-162 (Russian)

References

  1. 1. Moore KLF, Turesson I, Genell A, et al. Improved survival in myeloma patients–a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and Sweden. Haematologica. 2022;108(6):1640–51. doi: 10.3324/haematol.2021.280424.
  2. 2. Chacon A, Leleu X, Bobin A. 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. Cancers. 2023;15(7):1929. doi: 10.3390/cancers15071929.
  3. 3. Awada H, Thapa B, Awada H, et al. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells. 2021;10(8):1961. doi: 10.3390/cells10081961.
  4. 4. Maura F, Bergsagel PL. Molecular Pathogenesis of Multiple Myeloma: Clinical Implications. Hematol Oncol Clin North Am. 2024;38(2):267–79. doi: 10.1016/j.hoc.2023.12.010.
  5. 5. Cazaubiel T, Mulas O, Montes L, et al. Risk and Response-Adapted Treatment in Multiple Myeloma. Cancers. 2020;12(12):3497. doi: 10.3390/cancers12123497.
  6. 6. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2001;56(3):M146–56. doi: 10.1093/gerona/56.3.m146.
  7. 7. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–95. doi: 10.1503/cmaj.050051.
  8. 8. Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068–74. doi: 10.1182/blood-2014-12-615187.
  9. 9. Engelhardt M, Domm A-S, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910–21. doi: 10.3324/haematol.2016.162693.
  10. 10. Isaacs A, Fiala M, Tuchman S, Wildes TM. A comparison of three different approaches to defining frailty in older patients with multiple myeloma. J Geriatr Oncol. 2020;11(2):311–5. doi: 10.1016/j.jgo.2019.07.004.
  11. 11. Bringhen S, Mateos MV, Zweegman S, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980–7. doi: 10.3324/haematol.2012.075051.
  12. 12. Fernandez de Larrea C, Kyle RA, Durie BGM, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27(4):780–91. doi: 10.1038/leu.2012.336.
  13. 13. Musto P, Statuto T, Valvano L, et al. An update on biology, diagnosis and treatment of primary plasma cell leukemia. Expert Rev Hematol. 2019;12(4):245–53. doi: 10.1080/17474086.2019.1598258.
  14. 14. Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018;8(12):116. doi: 10.1038/s41408-018-0140-1.
  15. 15. Royer B, Minvielle S, Diouf M, et al. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2016;34(18):2125–32. doi: 10.1200/JCO.2015.63.1929.
  16. 16. Musto P, Simeon V, Martorelli MC, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia. 2014;28(1):222–5. doi: 10.1038/leu.2013.241.
  17. 17. Parrondo RD, Roy V, Sher T, et al. Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. Case Rep Hematol. 2020;2020:4360926. doi: 10.1155/2020/4360926.
  18. 18. Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883–98. doi: 10.1038/s41375-018-0209-7.
  19. 19. Ramadas P, Williams M, Duggan DB. Plasmablastic Lymphoma or Plasmablastic Myeloma: A Case of Post-Transplant Lymphoproliferative Disorder. Case Rep Hematol. 2021;2021:4354941. doi: 10.1155/2021/4354941.
  20. 20. Larsen JT, Chee CE, Lust JA, et al. Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. Blood. 2011;118(10):2702–7. doi: 10.1182/blood-2011-03-341933.
  21. 21. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–107. doi: 10.1002/ajh.26590.
  22. 22. Thakurta A, Ortiz M, Blecua P, et al. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood. 2019;133(11):1217–21. doi: 10.1182/blood-2018-10-880831.
  23. 23. Walker BA, Mavrommatis K, Wardell CP, et al. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019;33(1):159–70. doi: 10.1038/s41375-018-0196-8.
  24. 24. Perrot A, Corre J, Avet-Loiseau H. Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. Am Soc Clin Oncol Educ Book. 2018;38:675–80. doi: 10.1200/EDBK_200879.
  25. 25. Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28(3):675–9. doi: 10.1038/leu.2013.225.
  26. 26. Walker BA, Boyle EM, Wardell CP, et al. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015;33(33):3911–20. doi: 10.1200/JCO.2014.59.1503.
  27. 27. Abdallah NH, Binder M, Rajkumar SV, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12(1):1–9. doi: 10.1038/s41408-022-00611-x.
  28. 28. Yang P, Zhou F, Dong Y, et al. The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma. HemaSphere. 2023;7(4):e857. doi: 10.1097/HS9.0000000000000857.
  29. 29. Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360–76. doi: 10.1016/j.mayocp.2013.01.019.
  30. 30. Neben K, Lokhorst HM, Jauch A, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940–8. doi: 10.1182/blood-2011-09-379164.
  31. 31. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–52. doi: 10.1056/NEJMoa1411321.
  32. 32. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621–31. doi: 10.1056/NEJMoa1505654.
  33. 33. Moreau P, Masszi T, Grzasko N, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374(17):1621–34. doi: 10.1056/NEJMoa1516282.
  34. 34. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5):679–86. doi: 10.1182/blood-2010-02-268862.
  35. 35. Gay F, Cerrato C, Petrucci MT, et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. J Clin Oncol. 2019;37(15_suppl):8002. doi: 10.1200/JCO.2019.37.15_suppl.8002.
  36. 36. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936–45. doi: 10.1182/blood.2020005288.
  37. 37. Mateos M-V, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132–41. doi: 10.1016/S0140-6736(19)32956-3.
  38. 38. Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104–15. doi: 10.1056/NEJMoa1817249.
  39. 39. Stadtmauer EA, Pasquini MC, Blackwell B, et al. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019;37(7):589–97. doi: 10.1200/JCO.18.00685.
  40. 40. Cavo M, Gay F, Beksac M, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7(6):e456–e468. doi: 10.1016/S2352-3026(20)30099-5.
  41. 41. Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102–8. doi: 10.1182/blood-2015-08-662627.
  42. 42. Pawlyn C, Cairns D, Kaiser M, et al. The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2020;34(2):604–12. doi: 10.1038/s41375-019-0595-5.
  43. 43. O’Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222–30. doi: 10.1111/bjh.15261.
  44. 44. Hoff FW, Banerjee R, Khan A, et al. Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma. Blood. 2023;142(Suppl 1):544. doi: 10.1182/blood-2023-178950.
  45. 45. Banerjee R, Wang B, Anderson LD, et al. Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. Blood Cancer J. 2023;13(1):1–3. doi: 10.1038/s41408-023-00937-0.
  46. 46. Bhutani M, Usmani SZ. Quadruplets come of age for newly diagnosed multiple myeloma. Lancet. 2020;395(10218):94–6. doi: 10.1016/S0140-6736(19)33063-6.
  47. 47. Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood. 2011;117(11):3025–31. doi: 10.1182/blood-2010-09-307645.
  48. 48. Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. Haematologica. 2018;103(2):197–211. doi: 10.3324/haematol.2017.174573.
  49. 49. Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57–73. doi: 10.1016/S1470-2045(18)30687-9.
  50. 50. Goldschmidt H, Mai EK, Durig J, et al. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020;34(7):1853–65. doi: 10.1038/s41375-020-0724-1.
  51. 51. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. doi: 10.1016/S1470-2045(16)30206-6.
  52. 52. Derman BA, Fonseca R. Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematol Oncol Clin North Am. 2024. doi: 10.1016/j.hoc.2023.12.009.
  53. 53. Fan H, Wang B, Shi L, et al. Monitoring minimal residual disease in patients with multiple myeloma by targeted tracking serum M-protein using mass spectrometry (EasyM). Clin Cancer Res. 2024;30(6):1131–42. doi: 10.1158/1078-0432.CCR-23-2767.
  54. 54. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017;3(1):28–35. doi: 10.1001/jamaoncol.2016.3160.
  55. 55. Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016;51(12):1565–8. doi: 10.1038/bmt.2016.222.
  56. 56. Lahuerta J-J, Paiva B, Vidriales M-B, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol. 2017;35(25):2900–10. doi: 10.1200/JCO.2016.69.2517.
  57. 57. Owen RG. Minimal residual disease (MRD) in multiple myeloma: prognostic and therapeutic implications (including imaging). HemaSphere. 2019;3(Suppl):124–6. doi: 10.1097/HS9.0000000000000243.
  58. 58. Goicoechea I, Puig N, Cedena M-T, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021;137(1):49–60. doi: 10.1182/blood.2020006731.
  59. 59. Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–64. doi: 10.1182/blood-2018-06-858613.
  60. 60. Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2022;40(25):2901–12. doi: 10.1200/JCO.21.01935.
  61. 61. Dhakal B, Usmani S. Daratumumab and Lenalidomide Maintenance Guided by Minimal Residual Disease in Multiple Myeloma. Hematologist. 2021;18(6). doi: 10.1182/hem.V18.6.202166.
  62. 62. Askeland FB, Rasmussen A-M, Lysen A, et al. P889: Will outcome improve by treating multiple myeloma patients at MRD relapse? the remnant study (relapse from MRD negativity as indication for treatment). HemaSphere. 2022;6(Suppl):781–2. doi: 10.1097/01.HS9.0000846432.28047.c0.
  63. 63. Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019;380(18):1726–37. doi: 10.1056/NEJMoa1817226.
  64. 64. Moreau P, Zweegman S, Perrot A, et al. Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study. Blood. 2019;134(Suppl 1):692. doi: 10.1182/blood-2019-123143.
  65. 65. Dhakal B, Sharma S, Balcioglu M, et al. Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse. Front Oncol. 2022;12:786451. doi: 10.3389/fonc.2022.786451.
  66. 66. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.
  67. 67. Walker BA, Mavrommatis K, Wardell CP, et al. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018;132(6):587–97. doi: 10.1182/blood-2018-03-840132.
  68. 68. Ernst T, Aebi S, Zander A, Zander T. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance. BMJ Case Rep. 2022;15(4):e246264. doi: 10.1136/bcr-2021-246264.
  69. 69. Sharman JP, Chmielecki J, Morosini D, et al. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014;14(5):e161–3. doi: 10.1016/j.clml.2014.06.004.
  70. 70. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25(1):91–101. doi: 10.1016/j.ccr.2013.12.015.
  71. 71. Srkalovic G, Hussein MA, Hoering A, et al. A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434. Cancer Med. 2014;3(5):1275–83. doi: 10.1002/cam4.276.
  72. 72. Yordanova A, Hose D, Neben K, et al. Sorafenib in patients with refractory or recurrent multiple myeloma. Hematol Oncol. 2013;31(4):197–200. doi: 10.1002/hon.2043.
  73. 73. Badawi M, Coppola S, Eckert D, et al. Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety. Hematol Oncol. 2024;42(1):e3222. doi: 10.1002/hon.3222.
  74. 74. Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017;92(4):578–98. doi: 10.1016/j.mayocp.2017.01.003.
  75. 75. Kumar SK, Harrison SJ, Cavo M, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630–42. doi: 10.1016/S1470-2045(20)30525-8.
  76. 76. Bahlis NJ, Baz R, Harrison SJ, et al. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). J Clin Oncol. 2021;39(32):3602–12. doi: 10.1200/JCO.21.00443.
  77. 77. Andreozzi F, Dragani M, Quivoron C, et al. Precision Medicine Approach Based on Molecular Alterations for Patients with Relapsed or Refractory Multiple Myeloma: Results from the MM-EP1 Study. Cancers. 2023;15(5):1508. doi: 10.3390/cancers15051508.
  78. 78. Abdallah N, Rajkumar SV, Greipp P, et al. Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. Blood Cancer J. 2020;10(8):82. doi: 10.1038/s41408-020-00348-5.
  79. 79. Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015;125(9):1411–7. doi: 10.1182/blood-2014-11-612069.
  80. 80. Bobin A, Manier S, De Keizer J, et al. P891: Ixazomib, Pomalidomide and Dexamethasone (IXPD) In Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. HemaSphere. 2022;6(Suppl):783–4. doi: 10.1097/01.HS9.0000846440.48761.8d.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Copyright (c) 2025 Clinical Oncohematology